medRxiv preprint doi: https://doi.org/10.1101/2022.12.15.22283503; this version posted December 15, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

1	Long-term	neutralizing	antibody	dynamics	against	SARS-CoV-2 in
---	-----------	--------------	----------	----------	---------	---------------

2 symptomatic and asymptomatic infections: a systematic review and

3 meta-analysis

- 4
- 5 Wanying Lu¹*, Nan Zheng¹*, Xinhua Chen¹, Ruijia Sun¹, Jiayi Dong¹, Shijia Ge²,

6	Xiaowei	Deng ¹ ,	Hongjie	Yu ^{1,3†}
---	---------	---------------------	---------	--------------------

- 7
- 8 1. Fudan University, Key Laboratory of Public Health Safety, Ministry of Education,
- 9 Shanghai, China
- 10 2. Department of Infectious Diseases, Shanghai Key Laboratory of Infectious
- 11 Diseases and Biosafety Emergency Response, National Medical Center for Infectious
- 12 Diseases, Huashan Hospital, Fudan University, Shanghai, China
- 13 3. Shanghai Institute of Infectious Disease and Biosecurity, School of Public Health,
- 14 Fudan University, Shanghai, China

15

- 16 *Contributed equally as co-first authors
- 17 Corresponding author:
- 18 Hongjie Yu, E-mail: yhj@fudan.edu.cn

- 20 Abstract: 314 words
- 21 Main text: 3,561 words
- 22 Running Title: Review of long-term neutralizing antibody dynamics against natural NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 SARS-CoV-2 infections

- 25 Disclaimer: The views expressed are those of the authors and do not necessarily
- 26 represent the institutions with which the authors are affiliated.

27 Summary

28 Background

29 The kinetics of the neutralizing antibody response against SARS-CoV-2 is crucial for

- 30 responding to the pandemic as well as developing vaccination strategies. We aimed to
- 31 fit the antibody curves in symptomatic and asymptomatic individuals.

32 Methods

- 33 We systematically searched PubMed, Embase, Web of Science, and Europe PMC for
- articles published in English between Jan 1, 2020, and Oct 2, 2022. Studies evaluating
- 35 neutralizing antibody from people who had a natural SARS-CoV-2 infection history
- 36 were included. Study quality was assessed using a modified standardized scoring
- 37 system. We fitted dynamic patterns of neutralizing antibody using a generalized
- 38 additive model and a generalized additive mixed model. We also used linear
- 39 regression model to conduct both univariate and multivariable analyses to explore the
- 40 potential affecting factors on antibody levels. This study is registered with
- 41 PROSPERO, CRD42022348636.

42 **Results**

43 7,343 studies were identified in the initial search, 50 were assessed for eligibility after

44 removal of duplicates as well as inappropriate titles, abstracts and full-text review,

- 45 and 48 studies (2,726 individuals, 5,670 samples) were included in the meta-analysis
- 46 after quality assessment. The neutralization titer of people who infected with SARS-
- 47 CoV-2 prototype strain peaked around 27 days (217.4, 95%CI: 187.0-252.9) but
- 48 remained below the Omicron BA.5 protection threshold all the time after illness onset

49	or confirmation. Furthermore, neither symptomatic infections nor asymptomatic
50	infections could provide over 50% protection against Omicron BA.5 sub-lineage. It
51	also showed that the clinical severity and the type of laboratory assays may
52	significantly correlated with the level of neutralizing antibody.
53	Conclusions
54	This study provides a comprehensive mapping of the dynamic of neutralizing
55	antibody against SARS-CoV-2 prototype strain induced by natural infection and
56	compared the dynamic patterns between prototype and variant strains. It suggests that
57	the protection probability provided by natural infection is limited. Therefore, timely
58	vaccination is necessary for both previously infected symptomatic and asymptomatic
59	individuals.
60	
61	Key words
62	COVID-19; SARS-CoV-2; natural infection; neutralizing antibodies; dynamic;

63 symptomatic; asymptomatic

64 Introduction

65	Corona Virus Disease 2019 (COVID-19) is an acute respiratory infectious diseases
66	caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Parts of
67	COVID-19 patients develop symptoms such as fever, cough, and headache, but more
68	individuals may show no symptoms all the time. These asymptomatic individuals
69	account for a larger proportion yet they are harder to be found ¹ . From the first
70	outbreak in 2020 to the present, over 615 million cases have been caused ² and the
71	pathogen, has undergone several mutations and derives many variants over time as
72	well. WHO has paid special attention to Alpha (B.1.1.7), Beta (B.1.351), Gamma
73	(P.1), Delta (B.1.617.2) and Omicron (B.1.1.529), which has been listed as Variants of
74	Concern (VOCs) ³ . In January 2022, Omicron BA.1 sub-lineage was taking over the
75	Delta variant and becoming dominant globally. Gradually, BA.2 and its constituent
76	sub-lineages, such as BA.2.12.1, are overtaking BA.1 as the dominant variant globally.
77	More recent two sub-lineages BA.4 and BA.5 gradually became prevalent since June
78	2022, with the BA.5 being the dominantly circulating strains around the world.
79	Existing evidence suggests that there are more than 60
80	substitutions/deletions/insertions in Omicron ⁴ , with fifteen mutations located in the
81	receptor binding domain (RBD), a region that mediates virus attachment to the
82	angiotensin converting enzyme 2 (ACE2) receptor on target cells and is the principal
83	target of neutralizing antibody that contributes to protection against SARS-CoV-2 ^{5,6} .
84	These mutations give Omicron variant increased transmissibility and enhance its
85	immune-escape ability, which made it the major circulating variantcurrently ³ .

87	After infected with SARS-CoV-2, individuals produce neutralizing antibody, which is
88	part of the humoral response and prevents the interaction of infectious particles with
89	host cells by interfering with virion binding to receptors and blocking virus uptake
90	into host cells ⁷ . Therefore, neutralizing antibody produced in infected individuals may
91	protect them from reinfection to a certain extent. In other words, neutralizing antibody
92	is likely to be a key correlate of immune protection ⁸ . However, neutralizing antibody
93	level may be affected by age and clinical severity, and as neutralizing antibody titer
94	declines over time, its protection diminishes as well ⁹ . When neutralizing antibody
95	drop below a certain level, reinfection may occur ¹⁰ . To maintain effective neutralizing
96	antibody levels, vaccination is a good way. For the general population, a booster dose
97	or even a fourth dose is recommended nowadays. However, for individuals who have
98	ever been infected, only a few countries have defined clear vaccination strategies and
99	these strategies differ a lot across settings. For example, China recommends COVID-
100	19 convalescents to vaccinate one dose six months after infection ¹¹ , while the United
101	States recommends delaying the next dose for three months after infection ¹² .
102	
103	Considering the limited vaccine resources and the fairness of distribution, when and
104	how to vaccinate are urgent issues for COVID-19 convalescents, which requires
105	studies on antibody kinetics and immune protection in natural SARS-CoV-2
106	infections. At present, there are few reviews that quantitatively and comprehensively
107	summarized the long-term dynamics of neutralizing antibody titer in COVID-19

108	convalescents or asymptomatic infections, neither for prototype strain nor for other
109	variants. The existing systematic reviews and meta-analysis are based on limited
110	numbers of studies, which make the summary of the antibody kinetics limited to the
111	first few months after infection and lack comparability between different virus
112	neutralization assays ¹³⁻¹⁶ .
113	
114	In this study, we systematically collected data on time-varying neutralizing antibody
115	from people who had a natural SARS-CoV-2 infection history, including symptomatic
116	COVID-19 convalescents and asymptomatic infections. Based on collected data, we
117	fitted dynamic patterns of neutralizing antibody using a generalized additive model
118	(GAM) and a generalized additive mixed model (GAMM), estimated the peak times
119	and detectable duration and explored the potential effects that age group, clinical
120	severity and neutralization assays on antibody levels using both univariate and
121	multivariable analyses. We also compared the differences showed in kinetic patterns
122	between the prototype strain and variants.
123	
124	Methods
125	Search strategy and selection criteria
126	According to the Preferred Reporting Items for Systematic Reviews and Meta-
127	Analyses protocols ¹⁷ , we systematically did a literature review from three peer-
128	reviewed databases (PubMed, Embase, and Web of Science) and one preprint sever

129 (Europe PMC). The key search terms used were as follows: "SARS-CoV-2",

130	"neutralizing antibody",	"dynamic",	"kinetics", "symptomatic", a	and "asymptomatic".
-----	--------------------------	------------	------------------------------	---------------------

- 131 Detailed search terms were listed in **Supplementary Table 1**. Two independent
- 132 researchers (WL, NZ) assessed all retrieved papers published in English from Jan 1,
- 133 2020 to Oct 2, 2022. A third researcher (XC) was consulted when the two reviewers
- 134 disagreed on study assessment. We included studies that reported neutralizing
- antibody against SARS-CoV-2 prototype or variant strains by using serum or plasma
- 136 collected from symptomatic and asymptomatic individuals with virologically or
- 137 serologically-confirmed SARS-CoV-2 infections. Studies that investigated
- immunogenicity among specific population, such as pregnant women, cancer people,
- 139 immunodeficient patients, would be excluded. Detailed inclusion and exclusion
- 140 criteria were listed in **Supplementary Table 2**. This study was registered with
- 141 PROSPERO (no. CRD42022348636).
- 142

143 **Quality assessment**

Based on the Newcastle–Ottawa Scale (NOS)¹⁸ scoring system recommended by the 144 Cochrane Collaboration, we developed a revised scoring system to assess the study 145 quality. We comprehensively assessed study design (e.g., clear criteria and definition), 146 laboratory assay (e.g., validated neutralization assay), and outcome interpretation (e.g., 147 clear definition of sampling time) for each included study. The scoring system has a 148 total of nine items, with one point assigned for each item. A score of 0-3 was 149 considered a low-quality (grade C) study, a score of 4-6 was considered a moderate-150 quality (grade B) study, and a score of 7–9 was considered a high-quality (grade A) 151

study Detailed scoring system were listed in Supplementary Table 3. Only high and
 moderate-quality literatures were included in this study.

154

155 Data extraction

156	For eligible studies,	two researchers	(WL, NZ)	extracted the	following data	using a

157 standardized electronic data collection form: published journal or preprints severs,

title, first author's name, study location, study design, study participants, sample sizes,

sampling time, age, sex, race, ethnicity, underlying conditions, clinical severity,

160 details of laboratory testing methods including neutralization assays used, sample type

161 (sera or plasma), and other factors that may affect the serological results, such as

162 dilution factor, number of duplicates, cell line, virus titer used in the assay and the

163 individual antibody titer that neutralizes or inhibits 50% of the virus(e.g., NT₅₀,

164 PRNT₅₀). For each included study, we summarized its study participants, laboratory

165 methods, and outcome in **Supplementary Table 4**. Pre-trained researchers digitized

166 individual titer values from the figures in articles if titer were not available in table

167 format¹⁹. We made reliable assumptions according to the information of the locally

168 circulating viruses and the time when the variants begin to circulate in the region if

169 the exact virus lineage causing the infection for some participants is unknown.

170 Besides, if key information, such as the details of laboratory testing method, was not

- 171 reported in the paper, we will contact the corresponding author via email for data
- 172 inquiry. For those individuals with titer lower than limit of detection, we assumed a

173 titer half that limit (e.g., a titer of 10 is assumed when "<20" was present)²⁰. For those

- 174 individuals with titer higher than limit of detection, we assumed a titer that limit (e.g.,
- 175 a titer of 1024 is assumed when ">1024" was present).
- 176

177 Data classification and synthesis

178	We classified	l multiple n	eutralization as	ssays used in	included	studies into three
-----	---------------	--------------	------------------	---------------	----------	--------------------

179 categories based on the type of virus (live or pseudo) used and the types of vectors

- 180 (lentivirus or vesicular stomatitis virus [VSV]) used in pseudovirus neutralization
- 181 assays: live virus neutralization assays, lentivirus-vector pseudovirus neutralization
- assays, and VSV-vector pseudovirus neutralization assays. In each category of assay,
- 183 we further stratified study participants into two groups based on the presence or
- absence of symptoms: (1) symptomatic individual²¹: a symptomatic individual is one
- 185 with laboratory-confirmed SARS-CoV-2 infection as determined by PCR and/or
- serology and with symptoms including but not limited to fever, cough, general

187 weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea,

188 anorexia/nausea/vomiting, diarrhea. (2) asymptomatic individual²²: an asymptomatic

189 individual is one with laboratory-confirmed SARS-CoV-2 infection as determined by

190 PCR and/or serology but with no symptoms whatsoever for the duration of infection.

191 The characteristics of the participants (e.g., age, clinical severity and comorbidities)

192 were defined as follows. We divided the ages into three groups: ≤ 15 , 16-60 and >60.

- 193 As for clinical severity in symptomatic cases, we distinguished between mild and
- 194 severe individuals according to the World Health Organization²³ and National
- 195 Institutes of Health²⁴. Standards were as follows: (1) severe case: the patient were

196	categorized into severe cases if they were attended to Intensive Care Unit (ICU),
197	received oxygen supplementation (decreased oxygen saturation (≤94%)), ventilation
198	treatment during the hospitalization, or developing of pneumonia. (2) mild case:
199	symptomatic but not severe case was classified as mild case. For comorbidities, we
200	only distinguished whether they have comorbidities instead of what or how many
201	comorbidities there were.

202

203 Data analysis

Titer of symptomatic and asymptomatic infection-induced SARS-CoV-2 neutralizing antibody were log-transformed before data analysis. Model fitting was carried out according to the types of virus strains, which confirmed by article report or gene sequencing. A generalized additive model with Gaussian distribution that allows for flexible specification of dependence of response to covariates was used to fit the kinetics of SARS-CoV-2 neutralizing antibody. The model was shown in Equation 1:

210
$$g[E(y_i)] = \alpha + \beta s(x_i) + \varepsilon, \quad (1)$$

211 Where $E(y_i)$ is mean neutralizing antibody titer against SARS-CoV-2, g is the log 212 link function, α is the intersect, $s(x_i)$ is the value at a given time x_i of a smoothing 213 spline basis, β is the vector of spline coefficient, and ε is the random error.

214

215 Considering of the individual random effects, we also presented a subset of matched 216 data of which sera were consecutively collected from the same individual, using

generalized additive mixed model to model the dynamic curves. We assumed the
Gaussian distribution of neutralizing antibody titer in symptomatic individuals while
Gamma distribution in asymptomatic individuals based on the type of distribution.
The specification for the GAMM smoothing model is defined as follows:

221
$$g[E(y_i)] = \alpha + \beta s(x_i) + Z_b + \varepsilon, \quad (2)$$

Where Z_b is the random effect. Comparisons between models were made based on Bayesian information criteria (BIC) and Akaike information criteria (AIC). Besides, we determined prototype strain and Omicron BA.5 sub-lineage protective threshold which defined as 50% protective neutralization level against virus infections based on previous studies^{25,26}.

227



analyses. The factors included age, sex, comorbidity, clinical severity and assays. For

all statistical tests, a two tailed p value of less than 0.05 was considered statistically

significant. We also compared the neutralizing antibody dynamic curves among

232 different virus strains based on the same laboratory assay and clinical severity. All

statistical analyses were done using R software (version 4.2.0).

234

235 **Results**

236 Study selection and data extraction

237 We identified a total of 4,550 studies after systematically searching multiple data

238	sources with 1,966 coming from peer-reviewed databases, and 2,584 from preprint
239	server (Figure 1). After screening titles, abstracts, and full-texts, 50 studies containing
240	a total of 2,726 individuals and 5,783 samples were included. After quality assessment,
241	there were 18 grade A (18/50, 36%), 30 grade B (30/50, 60%) and 2 grade C studies
242	(2/50, 4%), and studies classified as grade A and B were included into analysis
243	(Figure S1, Table S5). Among 48 studies, with prototype strain infections the
244	subjects accounted for the most (47 studies; 5,546 of 5,670 samples, 97.8%), followed
245	by Alpha strain infected individuals (2 studies; 110 of 5,670 samples, 1.9%) and
246	Omicron BA.2 sub-lineage infections (1 study; 14 of 5,670 samples, 0.2%). Live virus
247	neutralization assays were most common (27 of 48 studies, 56.3%), followed by
248	lentivirus-vector pseudovirus neutralization assays (15 of 48 studies, 31.2%) and
249	VSV-vector pseudovirus neutralization assays (6 of 48 studies, 12.5%). Most
250	participants were symptomatic cases (46 studies; 2,480/2,690 individuals, 92.2%;
251	5,281/5,670 samples, 93.1%), while asymptomatic individuals accounted for a
252	relatively small proportion (12 studies; 210/2,690 individuals, 7.8%; 389/5,670
253	samples, 6.9%).
254	
255	Antibody responses in prototype strain infections in live virus neutralization

256 assays

257 For the overall dynamic curve fitted with matched sera, titer peaked around 27 days

258 (217.4, 95%CI: 187.0-252.9) after illness onset or confirmation. It remained above the

detection limit of 10 after 479 days, dropped below the prototype strain protection

260	threshold (19) at day 467 after illness onset or confirmation and kept below the
261	Omicron BA.5 protection threshold (266) all the time (Figure 2A). As for the
262	dynamic curve in symptomatic and asymptomatic infections separately, antibody titer
263	of symptomatic convalescents peaked around 26 days (250.8, 95%CI: 214.8-292.7)
264	after illness onset, then declined (Figure 2B). Antibody titer of asymptomatic
265	individuals were consistently lower than that of symptomatic convalescents all the
266	time. It took 463 and 171 days for neutralization titer to drop to the prototype strain
267	protection threshold (19) respectively in symptomatic individuals and asymptomatic
268	individuals but both of them remained below the Omicron BA.5 protection threshold
269	(266) and above the detection limit of 10 during the whole follow-up period (Figure
270	2C). Results of all samples showed similarity to those of paired sera, with slight
271	difference mainly in the timing of peak and protection thresholds (Figure S2).
272	
273	Association between clinical outcomes and antibody responses in prototype
274	strain infections
275	In the univariate analyses, the levels of neutralizing antibody increased over age, with
276	the mean neutralization level of 47.9, 137.6 and 209.2 in the groups of \leq 15 years, 15-
277	60 years and > 60 years, respectively (Figure 3, Table S6). For different clinical
278	endpoints, the neutralization titer in mild cases was significantly higher than that of

- asymptomatic individuals, but lower than that of severe cases (p<0.001). The levels of
- 280 neutralizing antibody varied in the types of neutralization assays, with the neutralizing
- antibody tested by lentivirus-vector pseudovirus neutralization assays had the highest

282	titer, followed by VSV-vector pseudovirus and live virus neutralization assays. In the
283	multivariable analysis, after controlling potential biases, only clinical severity and
284	types of neutralization assays were statistically significant.

285

299

286 Comparison of neutralizing antibody responses between prototype strain and

- 287 variants
- 288 There are few eligible studies explore the antibody kinetics in individuals infected
- with variants, with only two studies for Alpha and one study for Omicron BA.2.
- 290 Considering the limited number of sample size, heterogeneity of study design, as well
- as different antibody detection method, we compare the pattern rather than the
- antibody level between prototype strain and variants. As for the comparison between
- 293 prototype and Alpha strains infections in lentivirus-vector pseudovirus neutralization
- assays, individual antibody titer was fitted up to 180 days and 122 days for prototype
- strain and Alpha strain, respectively. Overall, although the follow-up period was
- shorter in the study of Alpha variant, the dynamic patterns of the both were similar
- based on matched samples. Antibody titer of Alpha convalescents peaked around 33
- 298 days after symptom onset, while peaked around day 28 in prototype convalescents. It

kept waning for the next 90 days without signs of plateauing. Up to day 122 after

- 300 symptom onset, the antibody level of Alpha strain remained higher than that of the
- 301 prototype strain (**Figure 4**). As for the comparison between prototype strain and
- 302 Omicron BA.2 sub-lineage infections in live virus neutralization assays, matched
- individual antibody titer was available for up to 209 days and 52 days for prototype

304	strain and Omicron BA.2 sub-lineage, respectively. Antibody titer of Omicron BA.2
305	peaked at day 39, 10 days later than that of prototype convalescents, then showed a
306	downward trend Due to the short follow-up period of the Omicron BA.2 study, it was
307	difficult to compare the complete dynamic patterns with the prototype strain.
308	

309 **Discussion**

Our study systematically retrieved the data of neutralizing antibody titers in naturally 310 infected individuals, fitted the dynamic curves, and explored the factors associated 311 with antibody levels. We also compared antibody responses between prototype and 312 variant strains. We found neutralization titer peaked around 27 days (217.4, 95%CI: 313 187.0-252.9) after illness onset or confirmation but remained below the Omicron 314 BA.5 protection threshold all the time after illness onset or confirmation. Furthermore, 315 316 neither symptomatic infections nor asymptomatic infections could provide over 50% protection against Omicron BA.5 sub-lineage. Our results also showed that the 317 clinical severity and the type of laboratory assays may significantly correlated with 318 the level of neutralizing antibody. 319

320

Our study showed that neutralizing antibody in natural infection individuals could be detected at around 2 days after confirmation or onset of symptoms, peaked around 27 days, and then started to decline. The antibody level remained detectable (>1:10) for at least 16 months, which was consistent with previous studies that showed that neutralizing antibody could be detected at around 6-15 days after infection²⁷, reached

peak around 31-45 days²⁸, then started to decline^{14,16}, and remained near the detection 326 limit at around 360 days²⁹. As for the asymptomatic infections, we did not observe a 327 marked increase of antibody level during the acute phase. Since asymptomatic 328 individuals remain asymptomatic from exposure to infection and virus expulsion, 329 these individuals are often difficult to be captured by symptom-based surveillance. In 330 addition, because individuals are asymptomatic all the time, they usually do not 331 initiate to seek assistance in medical institutions, which increases the difficulty of 332 early identification of asymptomatic individuals. Most of the studies included in this 333 study were hospital-based follow-up studies, so it was very hard to identify 334 asymptomatic individuals in the early stage of exposure, nor to better quantify the 335 trend of rapidly increasing neutralizing antibody levels during this period. As for the 336 dynamic patterns of variant strains, we did not compare the antibody levels 337 338 considering the heterogeneity between studies, such as characteristic of participants and laboratory assays. We only compared the dynamic curves, which were similar to 339 340 the patterns of prototype strain. Long-term follow-up studies are needed to determine the dynamic curves of the variant strains. 341

342

In our study, we found neutralization titer remained under the Omicron BA.5 protection threshold all the time after confirmation. A test-negative, case-control study showed that the protection probability against Omicron BA.5 infection and symptomatic infection was 33.5% (95% CI: 29.3-37.5%) and 38.1% (95% CI: 27.7-46.9%) separately at 493 and 496 days after infection in individuals who previously

infected pre-omicron strain³⁰. Another study, which estimated the protection effect in 348 a population with hybrid immunity (previous infection and vaccination), showed that 349 the protection effect against BA.5 infection was 51.6% (95% CI: 50.6-52.6%) in 350 Wuhan-Hu-1 strain infected individuals³¹. Results of these studies suggested that the 351 antibody level after natural infection with the prototype strain could not provide 50% 352 protection probability against Omicron BA.5 infection, which were similar to that of 353 our study. So the COVID-19 vaccines should be administered as soon as possible to 354 obtain effective protection. Like a special "infection", the COVID-19 vaccine 355 effectiveness or efficacy against the prototype strain are often compared with the 356 protection probability of natural infection. One study showed that the effectiveness 357 against BA.5 hospitalization was 47.4% (19.9-65.5%) within 3-4 months and 19.3% 358 (6.3-30.5%) over 9 months³². The effectiveness against BA.5 infection would be 359 lower²⁵. It was similar to our study, suggesting that neutralizing antibody levels in 360 naturally infected individuals as well as primary vaccinated population may not 361 provide 50% protection probability against BA.5. This was consistent with previous 362 study that showed the probability of protection after natural infection was similar to 363 the effectiveness of two doses vaccination³³. 364

365

Our study showed that neutralizing antibody levels are positively correlated with clinical severity, which was consistent with previous study³⁴ Since inflammatory cytokines may be related to higher levels of neutralizing antibody in severe cases. Severe cases tend to have high systemic level of pro-inflammatory cytokines, which

370	has been shown to correlate with antibody levels to COVID-19 ³⁵ . Moreover,
371	inflammatory cytokines are closely related to humoral immunity, and studies have
372	shown that IFN- γ^{36} , IL-12 ³⁷ , and IL-17 ³⁸ play important roles in B-cell development.
373	Age was statistically significant in univariate analysis, indicating older age was
374	associated with higher neutralizing antibody levels, but not in multivariate analysis.
375	This could be because there were more severe cases in the elderly population, and
376	clinical severity is positively correlated with neutralizing antibody levels, so antibody
377	levels are higher in the elderly population.

378

Our study had several limitations. First, there were heterogeneity among the studies, 379 but we minimized them by conducting subgroup analyses according to the population 380 characteristic and laboratory assays. Second, the exact virus lineage causing the 381 382 infection for some participants is unknown. However, we have made reliable assumptions according to the information of the local circulating viruses and the time 383 when the variants began to circulate in the region. Third, relatively fewer sera beyond 384 200 days after onset of illness was collected to define the late antibody waning 385 kinetics. We also have relatively fewer numbers of asymptomatic infections compared 386 to those with symptomatic disease. Thus, our findings on asymptomatic infections 387 need to be interpreted with caution. Studies on the long-term dynamic changes of 388 antibody in asymptomatic infected patients should be strengthened in the future. 389

390

391 In conclusion, our study provided a comprehensive mapping of the dynamic of

392	neutralizing antibody against SARS-CoV-2 prototype strain induced by natural
393	infection and compared the dynamics between protype and variant strain. Our
394	findings suggested that the antibody level of symptomatic cases reached peak level at
395	day 26 and then decreased, but it failed to provide 50% protection probability against
396	Omicron BA.5, same as that of asymptomatic individuals. At present, the key
397	question is to study the long-term dynamic changes of antibody after natural infection
398	of mutant strains so as to understand when and how to vaccinate COVID-19
399	convalescents, whether widespread immunization would lead to a temporary drop in
400	morbidity, and how long it would take for another major outbreak to occur.
401	
402	Acknowledgements

- 403 This study was supported by grants from the Key Program of the National Natural
- 404 Science Foundation of China (grant 82130093 to H.Y.).

405 **References**

- 406 1. Chen X, Chen Z, Azman AS, et al. Serological evidence of human infection with
- 407 SARS-CoV-2: a systematic review and meta-analysis. *The Lancet Global Health* 2021;

408 **9**(5): e598-e609.

- 409 2. WHO. WHO Coronavirus (COVID-19) Dashboard. 2022.
- 410 3. WHO. Tracking SARS-CoV-2 variants. 2022.
- 411 4. He X, Hong W, Pan X, Lu G, Wei X. SARS-CoV-2 Omicron variant:
- 412 Characteristics and prevention. *MedComm* (2020) 2021; **2**(4): 838-45.
- 413 5. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology,
- 414 Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A
- 415 Review. JAMA 2020; **324**(8): 782-93.
- 416 6. Starr TN, Greaney AJ, Hilton SK, et al. Deep Mutational Scanning of SARS-
- 417 CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding.
- 418 *Cell* 2020; **182**(5): 1295-310 e20.
- 419 7. Pang NY-L, Pang AS-R, Chow VT, Wang D-Y. Understanding neutralising

420 antibodies against SARS-CoV-2 and their implications in clinical practice. Military

- 421 *Medical Research* 2021; **8**(1): 47.
- 422 8. Addetia A, Crawford Katharine HD, Dingens A, et al. Neutralizing Antibodies
- 423 Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel
- 424 Outbreak with a High Attack Rate. *Journal of Clinical Microbiology* 2020; **58**(11):
- 425 e02107-20.
- 426 9. Lau EHY, Tsang OTY, Hui DSC, et al. Neutralizing antibody titres in SARS-

- 427 CoV-2 infections. *Nature communications* 2021; **12**(1): 63.
- 428 10. Hansen CH, Michlmayr D, Gubbels SM, Mølbak K, Ethelberg S. Assessment of
- 429 protection against reinfection with SARS-CoV-2 among 4 million PCR-tested
- 430 individuals in Denmark in 2020: a population-level observational study. *The Lancet*
- 431 2021; **397**(10280): 1204-12.
- 432 11. Group CCfDCaPC-VW. COVID-19 Vaccination Technical Guidelines (First
 433 Edition). 2021.
- 434 12. Prevention CfDCa. Getting a COVID-19 Vaccine. 2022.
- 435 13. Huang AT, Garcia-Carreras B, Hitchings MDT, et al. A systematic review of
- 436 antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and

437 association with severity. *Nature communications* 2020; **11**(1): 4704.

- 438 14. Post N, Eddy D, Huntley C, et al. Antibody response to SARS-CoV-2 infection in
- 439 humans: A systematic review. *PLOS ONE* 2021; **15**(12): e0244126.
- 440 15. Borremans B, Gamble A, Prager KC, et al. Quantifying antibody kinetics and
- 441 RNA detection during early-phase SARS-CoV-2 infection by time since symptom
- 442 onset. *Elife* 2020; **9**.
- 443 16. Arkhipova-Jenkins I, Helfand M, Armstrong C, et al. Antibody Response After
- 444 SARS-CoV-2 Infection and Implications for Immunity. *Annals of Internal Medicine*
- 445 2021; **174**(6): 811-21.
- 446 17. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic
- 447 review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic reviews

448 2015; **4**(1): 1.

449	18.	Wells	G,	Shea	Β,	O'Connell	D,	et al.	The	Newcastle	-Ottawa	Scale	(NOS)	for
-----	-----	-------	----	------	----	-----------	----	--------	-----	-----------	---------	-------	-------	-----

- 450 assessing the quality of nonrandomised studies in meta-analyses. Accessed 31 July
- 451 2022. <u>https://www.ohri.ca//programs/clinical_epidemiology/oxford.asp.</u>
- 452 19. WebPlotDigitizer 4.5. <u>https://apps.automeris.io/wpd/index.zh_CN.html</u> (accessed
- 453 2022/08/28).
- 454 20. Chen X, Chen Z, Azman AS, et al. Neutralizing Antibodies Against Severe Acute
- 455 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Induced by Natural
- 456 Infection or Vaccination: A Systematic Review and Pooled Analysis. Clinical
- 457 infectious diseases : an official publication of the Infectious Diseases Society of
- 458 *America* 2022; **74**(4): 734-42.
- 459 21. World Health Organization. WHO COVID-19: Case Definitions. 2020.
- 460 <u>https://www.who.int/publications/i/item/WHO-2019-nCoV-</u>
- 461 <u>Surveillance_Case_Definition-2020.2</u> (accessed 2020/12/16).
- 462 22. Meyerowitz EA, Richterman A, Bogoch, II, Low N, Cevik M. Towards an
- 463 accurate and systematic characterisation of persistently asymptomatic infection with
- 464 SARS-CoV-2. *The Lancet Infectious diseases* 2021; **21**(6): e163-e9.
- 465 23. World Health Organization. Clinical management of COVID-19: Living
- 466 guideline, 23 June 2022. 2022. https://www.who.int/publications/i/item/WHO-2019-
- 467 <u>nCoV-clinical-2022-1</u> (accessed 2022/6/23).
- 468 24. National Institutes of Health. Clinical Spectrum of SARS-CoV-2 Infection. 2021.
- 469 <u>https://www.covid19treatmentguidelines.nih.gov/</u> (accessed 2021/10/19).
- 470 25. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly

- 471 predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nature*472 *medicine* 2021; **27**(7): 1205-11.
- 473 26. Cheng SS, Mok CK, Li JK, et al. Plaque-neutralizing antibody to BA.2.12.1,
- 474 BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines,
- 475 natural infection and breakthrough infection. Journal of clinical virology : the official
- 476 *publication of the Pan American Society for Clinical Virology* 2022; **156**: 105273.
- 477 27. Koblischke M, Traugott MT, Medits I, et al. Dynamics of CD4 T Cell and
- 478 Antibody Responses in COVID-19 Patients With Different Disease Severity.
- 479 *Frontiers in medicine* 2020; **7**: 592629.
- 480 28. Isho B, Abe KT, Zuo M, et al. Persistence of serum and saliva antibody responses
- 481 to SARS-CoV-2 spike antigens in COVID-19 patients. *Science immunology* 2020;
 482 5(52).
- 29. Lin Y, Zhu J, Liu Z, et al. Kinetics of severe acute respiratory syndrome
 coronavirus 2 infection antibody responses. *Frontiers in immunology* 2022; 13:
 864278.
- 486 30. Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Protective Effect of Previous
- 487 SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants. *The New*488 *England journal of medicine* 2022.
- 489 31. Malato J, Ribeiro RM, Leite PP, et al. Risk of BA.5 Infection among Persons
- 490 Exposed to Previous SARS-CoV-2 Variants. The New England journal of medicine
- 491 2022; **387**(10): 953-4.
- 492 32. Collie S, Nayager J, Bamford L, Bekker LG, Zylstra M, Gray G. Effectiveness

- and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South
 Africa. *The New England journal of medicine* 2022; **387**(14): 1332-3.
- 495 33. Pilz S, Theiler-Schwetz V, Trummer C, Krause R, Ioannidis JPA. SARS-CoV-2
- 496 reinfections: Overview of efficacy and duration of natural and hybrid immunity.
- 497 *Environmental research* 2022; **209**: 112911.
- 498 34. Chia WN, Zhu F, Ong SWX, et al. Dynamics of SARS-CoV-2 neutralising
- 499 antibody responses and duration of immunity: a longitudinal study. The Lancet
- 500 *Microbe* 2021; **2**(6): e240-e9.
- 501 35. Wu F, Liu M, Wang A, et al. Evaluating the Association of Clinical
- 502 Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered
- 503 From Mild COVID-19 in Shanghai, China. JAMA internal medicine 2020; 180(10):
- 504 1356-62.
- 505 36. Abed NS, Chace JH, Fleming AL, Cowdery JS. Interferon-gamma regulation of
- 506 B lymphocyte differentiation: activation of B cells is a prerequisite for IFN-gamma-
- 507 mediated inhibition of B cell differentiation. *Cellular immunology* 1994; **153**(2): 356-
- 508 **66**.
- 37. Metzger DW. Interleukin-12 as an adjuvant for induction of protective antibody
 responses. *Cytokine* 2010; **52**(1-2): 102-7.
- 511 38. Shibui A, Shimura E, Nambu A, et al. Th17 cell-derived IL-17 is dispensable for
- 512 B cell antibody production. *Cytokine* 2012; **59**(1): 108-14.
- 513

Figure legends 514

Figure 1 Flowchart of study selection 515

- Flowchart of the selection of studies including time-varying neutralizing antibody 516
- data from Jan 1, 2020, to Oct 2, 2022. 517
- 518
- Figure 2 Neutralizing antibody responses in prototype strain infections in live 519

virus neutralization assays 520

- A) All individuals; B) Symptomatic individuals; C) Asymptomatic individuals. Black 521
- lines represent detection limit (10); green lines, prototype strain protection threshold 522
- (19); blue lines, Omicron BA.5 protection threshold (266). 523
- 524

Figure 3 Neutralizing antibody responses in prototype strain infections among 525

526 different characteristics

- A) Age; B) Sex; C) Comorbidity; D) Clinical severity; E) Assay. 527
- 528

Figure 4 Comparison of neutralizing antibody responses between prototype 529

strain and variants 530

- 531 A) Prototype and Alpha strains; B) Prototype strain and Omicron BA.2 sub-lineage.
- Black lines represent detection limit of prototype strain (10); red line, detection limit 532
- of Alpha strain (60); blue line, detection limit of Omicron BA.2 sub-lineage (20). 533
- 534

Figure 1 536



Figure 2 539



Figure 3 542



543 544 Time sin

Ilnoce ot o n (davs)

Figure 4 545

